Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Moderna
Biotechnology
US mRNA specialist Moderna today announced that its Phase III trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints. 10 June 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved UK pharma major GSK’s Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk. 10 June 2024
Pharmaceutical
In a blog post, the general counsel of European trade group EFPIA - the European Federation of Pharmaceutical Industries and Associations - has argued for effective incentives to be included in the EU general pharmaceutical legislation. 10 June 2024
Biotechnology
Scottish immune-oncology company Macomics has appointed Simon Dew as chief business officer (CBO). 10 June 2024
Biotechnology
Among important research news last week, Structure Therapeutics released strong Phase IIa trial results for its weight management investigational drug GSBR-1290, and US biotech BridgeBio Pharma announced encouraging Phase II data supporting its candidate infigratinib as a treatment for achondroplasia, the most common form of dwarfism. On the regulatory front, hallucinogenic medicines developer Lykos Therapeutics suffered a major setback last week, when a US Food and Drug Administration (FDA) advisory panel voted against approving its midomafetamine for the treatment of post traumatic distress disorder. There was good news for Geron Corp, whose myelodysplastic syndrome drug imetelstat, now trade named Rytelo, was approved by the FDA. 9 June 2024
Pharmaceutical
Swiss pharma giant Roche on Friday announced new five-year data confirming the sustained efficacy and safety profile of Evrysdi (risdiplam) in children with Type 1 spinal muscular atrophy (SMA) from the open-label extension of the pivotal FIREFISH study. 8 June 2024
Biotechnology
Microbiome therapeutics company Seres Therapeutics has announced a memorandum of understanding with Nestlé Health Science to sell its Vowst (fecal microbiota spores, live-brpk) assets. 7 June 2024
Biotechnology
I-Mab has appointed Phillip Dennis as chief medical officer, overseeing the company's global clinical development efforts. 7 June 2024
Biotechnology
USA-based immuno-oncology firm Marengo Therapeutics today announced a second strategic partnership with French drugmaker Ipsen to advance precision T cell engagers (TCEs) from Marengo’s next-generation TriSTAR platform. 7 June 2024
Pharmaceutical
Abu Dhabi’s Department of Health has signed a Memorandum of Understanding (MoU) with AstraZeneca (LSE: AZN) to establish a world-class Rare Diseases Centre of Excellence (CoE) in the emirate. 7 June 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze